替吉奥在晚期大肠癌患者维持治疗的疗效观察

Observation of the efficacy of tegafur in the maintenance treatment of patients with advanced colorectal cancer

目的对替吉奥在晚期大肠癌患者维持治疗中的疗效进行观察。方法选取我院2016年8月~2017年8月收治的晚期大肠癌维持治疗患者共计76例,按照随机数字表法分为观察组和参照组,每组患者各38例,参照组患者常规化疗,观察组患者在常规化疗结束后使用替吉奥进行维持治疗,对比分析不同组别患者的疾病控制率和不良反应发生率。结果在治疗效果对比中,观察组患者疾病控制率为71.05%,参照组患者疾病控制率为65.78%,差异无统计学意义(P>0.05);在不良反应发生率对比中,观察组患者不良反应发生率为7.89%,参照组患者不良反应发生率为34.21%,经统计学比较分析差异有统计学意义(P<0.05)。结论尽管晚期大肠癌患者使用替吉奥进行维持治疗的疾病控制情况相比于常规化疗来说并不明显,但患者的不良反应发生率较低,安全性更高,具有临床应用价值,可予以使用和推广。

Objective To observe the efficacy of tegafur in the maintenance treatment of patients with advanced colorectal cancer.Methods A total of 76 patients with advanced colorectal cancer treated in our hospital from August 2016 to August 2017 were selected.According to the random number table method,the patients were divided into observation group and reference group,38 cases in each group.The patients in the reference group were treated with conventional chemotherapy,while the observation group was treated with tegafur after the end of conventional chemotherapy.The disease control rate and incidence of adverse reactions in different groups were compared and analyzed.Results In the comparison of therapeutic effect,the disease control rate of the observation group was 71.05%,and the disease control rate of the reference group was 65.78%,the difference was not statistically significant(P>0.05).In the comparison of the incidence of adverse reactions,the incidence of adverse reactions in the observation group was 7.89%,the incidence of adverse reactions in the reference group was 34.21%,and the difference between the two groups was statistically significant(P<0.05).Conclusion Although the control of the use of tegafur for patients with advanced colorectal cancer is not obvious compared with conventional chemotherapy,the incidence of adverse reactions in patients is low,safety is higher,and it is of clinical value.It can be used and popularized.